Causes of Autoimmune Autonomic Ganglionopathy
Autoimmune autonomic ganglionopathy (AAG) is caused by autoantibodies directed against the ganglionic nicotinic acetylcholine receptor (gAChR), specifically targeting the α3 and β4 subunits, which impairs synaptic transmission in autonomic ganglia 1, 2.
Primary Pathogenic Mechanism
The fundamental cause is an antibody-mediated autoimmune attack on the ganglionic acetylcholine receptors located throughout the autonomic nervous system 3, 4. These antibodies:
- Bind specifically to the α3 subunit of the ganglionic AChR 2
- Inhibit ganglionic AChR currents and impair synaptic transmission in sympathetic, parasympathetic, and enteric autonomic ganglia 2
- Do not cross-react with other nicotinic acetylcholine receptors, making them highly specific 2
The mechanism is a postsynaptic channelopathy rather than neuronal destruction—autopsy evidence demonstrates preserved sympathetic ganglia and intact postganglionic fibers despite severe functional impairment 5. This distinguishes AAG from neurodegenerative causes of autonomic failure.
Triggering Factors and Associations
While the autoantibody production is the direct cause, several potential triggers and associations have been identified:
Infectious/Post-Infectious Triggers
- COVID-19 infection and mRNA COVID-19 vaccination have been associated with autonomic dysfunction and potential AAG development 1
- The disease often presents with acute or subacute onset, suggesting a possible preceding trigger event 3
Cancer-Related
- Immune checkpoint inhibitors used in cancer therapy can cause dysautonomia as an immune-related adverse event 1
- This represents a form of iatrogenic immune activation leading to AAG
Autoimmune Associations
AAG shows overrepresentation of other autoimmune diseases in affected patients 6, suggesting a broader autoimmune diathesis may predispose to gAChR antibody development.
Important Clinical Context
The antibody titer correlates with disease severity at onset—high antibody levels are associated with more severe cardiovascular and urinary dysfunction 7. However, during follow-up, the correlation between antibody levels and clinical severity becomes less reliable 7.
Critical Diagnostic Caveat
Not all patients with clinical AAG test positive for gAChR antibodies 4. The prevalence of gAChR antibodies in AAG is not definitively established, and false-positive results can occur in conditions without overt autonomic dysfunction 4. Therefore, seronegative AAG exists and should not be excluded based solely on negative antibody testing when clinical features are compelling.
Pathological Evidence
Recent autopsy findings confirm that despite severe functional impairment, there is no histologic evidence of sympathetic nerve degeneration or neuronal loss 5. Only mild perivascular lymphocytic infiltration is observed, likely reflecting systemic illness rather than primary inflammatory destruction 5. This supports the concept that AAG is a functional channelopathy caused by antibody-mediated receptor blockade, not neuronal death.